

Form PTO-1449		ATTY DOCKET NO. 2081-0125P		APPLICATION NO. Unknown	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		APPLICANT Kent JORGENSEN, et al.		FILING DATE February	
				GROUP 1615	
<b>U.S. PATENT DOCUMENTS</b>					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
/G.K./	5 9 2 7 8 3 9	1998-10-27	Peterson, et al.		
	6 8 8 8 9 1 1	1996-01-16	Hong, et al.		
	4 8 2 2 3 8 2	1986-11-11	Hong, et al.		
	5 9 8 2 2 8 9	1994-04-28	Mayhew, et al.		
	6 8 3 2 2 8 2	1999-08-03	Franklin, et al.		
	6 8 8 5 1 5 9	1999-10-12	Mayhew, et al.		
	6 0 0 7 8 3 9	1999-12-28	Mayhew, et al.		
	5 8 8 2 8 7 9	1999-03-16	Needham		
	5 8 8 5 8 5 9	1999-11-16	Kozak		
	6 0 7 7 8 3 7	2000-10-24	Kozak		
	6 1 3 6 7 8 9	2000-10-24	Kozak		
/G.K./	6 1 6 8 0 8 9	2000-10-24	Kozak		
<b>FOREIGN PATENT DOCUMENTS</b>					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS
	ES 2 0 3 4 8 84	1994-03-01	SPAIN		
/G.K./	WO 99 0 8 0 1 8	1994-04-28	PCT		
/G.K./	WO 99 2 2 8 8 3	1994-10-13	PCT		
/G.K./	WO 99 0 2 1 2 0	1999-01-21	PCT		
/G.K./	WO 99 0 2 8 8 5	1999-01-21	PCT		
/G.K./	WO 99 1 8 7 8 1	1994-04-28	PCT		
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)					
/G.K./	"Therapeutic Activity of a Thioether-Lipid Conjugate of 1-β-D-Arabinofuranosylcytosine in Human Colorectal Cancer Xenografts", R. Herrmann, et al, Am. Assoc. Cancer Res., Vol. 52, No. 7, pp. 1865-1867 (1992)				
/G.K./	"Competitive Inhibition of Lipolytic Enzymes. IX. A comparative Study on the Inhibition of Pancreatic Phospholipases A <sub>2</sub> from Different Sources by (R)-2-acylamino Phospholipid Analogues", G. H. de Haas, et al, BBA - Lipids and Lipid Metabolism, NL/Elsevier Science BV., Vol. 1167, No. 3, 1993, pp. 281-288				
/G.K./	"The Chemical Synthesis of a Series of Ether Phospholipids From D-Mannitol and Their Properties", J Xia, et al, Tetrahedron: Asymmetry, Vol. 8, No. 18, pp. 3131-3142, 1997				
EXAMINER  /Gollamudi Kishore/			DATE CONSIDERED 02/20/2008		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

LRS/KR/sml

Form PTO-1449				ATTY DOCKET NO. 2081-0125P		APPLICATION NO. Unknown	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)				APPLICANT Kent JORGENSEN, et al.		FILING DATE February	
GROUP 1615							
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
/G.K./	5 8 5 9 2 2 8	1999-01-12	JANJIC et al.				
/G.K./	6 2 2 9 0 0 2	2001-05-08	JANJIC et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES NO	
<b>OTHER DOCUMENTS</b> (include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, abstract, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)							
/G.K./	"Cytotoxicity of Platelet Activating Factor and Related Alkyl-Phospholipid Analogs in Human Leukemia Cells, Polymorphonuclear Neutrophils, and Skin Fibroblasts", D. Hoffman, et al, Blood, Vol. 63, No. 3, 1984, pp. 545-552						
/G.K./	Enzymatic Degradation of Polymer Covered SOPC-Liposomes in Relation to Drug Delivery", J. Davidsen, et al, Symposium on Lipid and Surfactant Self-Assemblies: Structure, Dynamics and Reactions, Feb. 24-25, 2000, Uppsala, Sweden						
/G.K./	"Controlled Destabilization of Liposomal Drug Delivery Systems by Phospholipase A <sub>2</sub> ", J Davidsen, et al, Dec. 1999						
/G.K./	"Increased Cell-surface Receptor Expression on U-937 Cells Induced by 1-o-octadecyl-2-o-methyl-sn-glycero-3-phosphocholine", M. Pushkareva, et al, Cancer Immunol Immunother (2000) 48: 569-578						
/G.K./	"Ether Lipids in the Therapy of Cancer", R. Andreessen, Prog. Biochem, Pharmacol, Vol 22, pp. 118-131 1988						
/G.K./	"1-β-D-Arabinofuranosylcytosine-Phospholipid Conjugates As Prodrugs of Ara-C", C. Hong, et al, Cancer Drug Delivery, Vol. 1, No. 3, 1984, pp. 181-190						
/G.K./	"Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids", C. Hong, et al, J. Med. Chem. 1986, 29, 2038-2044						
/G.K./	"Phospholipid Antitumor Agents", W. Houlihan, et al., Medicinal Research Reviews, Vol. 15, No. 3, 157-223 (1995)						
/G.K./	"Antitumor Ether Lipids and Alkylphosphocholines", M. Lohmeyer, et al, Drugs of the Future, 1994, 19(11): 1021-1037						
/G.K./	"Growth Arrest vs. Direct Cytotoxicity and the Importance of Molecular Structure for the In vitro Anti-Tumor Activity of Ether Lipids", M. Lohmeyer, et al, British Journal of Cancer (1995) 72, pp. 277-286						
/G.K./	"Enhancement of Phospholipase A <sub>2</sub> Catalyzed Degradation of Polymer Grafted PEG-Liposomes: Effects of Lipopolymer-concentration and Chain-Length", K Jorgensen, et al., Pharmaceutical Research, Vol. 16, No. 9, 1999 pp. 1491-1493						
/G.K./	"Increase in Phospholipase A <sub>2</sub> Activity Towards Lipopolymer-Containing Liposomes, C. Vermehren, et al, BBA, 1998, pp.27-36						
EXAMINER			/Gollamudi Kishore/		DATE CONSIDERED		
					02/20/2008		
EXAMINER: initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							